Dong-A and Shanghai Zhongxi Sunve sign license agreement for Zydena

Published: 2011-08-12 06:56:00

Updated: 2011-08-12 06:56:00

Dong-A Pharmaceutical Co. said Tuesday that it has signed an agreement with Shanghai Zhongxi Sunve Pharmaceutical Co. based in China to market Dong-A’s orally-administered udenafil product, a phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED) in China.

“We are extremely pleased to see the marketing of Zydena in China. This is an important milestone in ou...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.